Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2026)

Contineum Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $20.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 10.29% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 10.29% decrease from a year earlier, with the FY2025 full-year figure at $75.6 million, up 244.54% from the prior year.
• Cash & Equivalents retreated to $20.2 million in Q1 2026 per CTNM's latest filing, from $75.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $77.2 million in Q2 2024 and bottomed at $15.5 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $22.2 million (2024), against an average of $35.4 million.
• Biggest YoY gain for Cash & Equivalents was 244.54% in 2025; the steepest drop was 73.09% in 2025.
• Year by year, Cash & Equivalents stood at $15.5 million in 2023, then jumped by 41.33% to $21.9 million in 2024, then soared by 244.54% to $75.6 million in 2025, then tumbled by 73.34% to $20.2 million in 2026.
• Per Business Quant, the three latest CTNM Cash & Equivalents figures stand at $20.2 million (Q1 2026), $75.6 million (Q4 2025), and $42.6 million (Q3 2025).